Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct 1;44(10):e363-e368.
doi: 10.1097/INF.0000000000004893. Epub 2025 Jun 6.

Accelerating Uptake of Optimal Antiretrovirals for Children and Adolescents Living With HIV in Nigeria, Tanzania, Uganda and Zambia Through Data-driven Quality Improvement Interventions

Stephanie Dowling  1 , Stephanie Hackett  2 , Lauren Simao  1 , Marisa Hast  2 , Neha Mehta  2 , Jessica Gross  2 , KaeAnne Parris  2 , Deborah Carpenter  2 , Jibrin Kama  3 , Leah Mtui  4 , Felton Mpasela  5 , Vennie Nabitaka  6 , Clement Adesigbin  7 , Michelle Adler  8 , Ivan Arinaitwe  9 , Uzoma Atu  7 , Lilian Babyebonela  3 , Estella Birabwa  10 , Uzoma Ene  11 , Omodele Johnson Fagbamigbe  11 , Thomas Fenn  9 , Simret Habtezgi  5 , Prudence Haimbe  5 , Akudo Ikpeazu  7 , Megumi Itoh  6   12 , James John  13 , Davies Kampamba  14 , Sylvester Kwilasa  15 , David Mabirizi  9 , Edward Machage  16 , Eleanor Magongo  17 , Chediel Mbonea  4 , Mwaba Mulenga  5 , Gloria Munthali  14 , Kebby Musokotwane  6   12 , Miriam Nakanwagi  17 , Sophie Nantume  8 , Esther Nazziwa  8 , Kelechi Ngwoke  6   12   18 , Esther Nkolo  19 , Iboro Nta  3 , Oluwatosin Oladokun  20 , Olanrewaju Olayiwola  21 , Daniel Oliver  9 , Dennis Onotu  11 , Chibuzor Onyenuobi  11 , Mastidia Rutaihwa  13 , Anath Rwebembera  15 , Nadia A Sam-Agudu  22   23 , Oluwakemi Sowale  3 , Evarist Twinomujuni  6 , Khozya D Zyambo  14 , Kanchana Suggu  1 , Carolyn Amole  1
Affiliations

Accelerating Uptake of Optimal Antiretrovirals for Children and Adolescents Living With HIV in Nigeria, Tanzania, Uganda and Zambia Through Data-driven Quality Improvement Interventions

Stephanie Dowling et al. Pediatr Infect Dis J. .

Abstract

Background: Limited access to disaggregated pediatric antiretroviral therapy (ART) data by weight, as recommended by the World Health Organization, made treatment optimization challenging. This article describes the treatment optimization interventions for children and adolescents living with HIV (CALHIV) implemented by the Faith-based Action for Scaling-Up Testing and Treatment for Epidemic Response (FASTER) initiative, assesses changes in optimal ART and viral load suppression (VLS) over time and offers lessons learned.

Methods: During January 2020-December 2021, FASTER supported treatment optimization in 245 high-burden facilities across Nigeria, Tanzania, Uganda and Zambia. We collected and analyzed quarterly ART uptake for CALHIV 0-19 years by regimen and weight band (3-19.9, 20-29.9 and ≥30 kg) as the primary outcome in FASTER-supported sites to inform course correction. We also analyzed VLS and viral load coverage among CALHIV between FASTER-supported and non-FASTER-supported sites.

Results: Quarterly ART data analysis informed targeted ART training and mentorship of 1230 health workers and 4927 community members. A total of 225 facilities reported regimen data, covering 30,208 CALHIV. The proportion of CALHIV on optimized treatment regimens increased from 49.0%-66.4% at baseline to 82.6%-91.9% at endline across countries. VLS increased from 79% to 91% in FASTER sites and 77% to 90% in non-FASTER sites.

Conclusions: We saw dramatic improvements in optimal ART uptake overall. FASTER-supported interventions, such as data use and training, may have contributed to these increases. Optimal ART uptake likely contributed to improvements in VLS observed in both FASTER and non-FASTER sites given efforts to drive nationwide scale-up of optimal ART.

Keywords: adolescent HIV; pediatric HIV; quality improvement; treatment optimization.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

References

    1. UNAIDS. UNAIDS Data 2023. 2023. Available from: https://www.unaids.org/sites/default/files/media_asset/2022-global-aids-... . Accessed January 31, 2024.
    1. Penazzato M, Watkins M, Morin S, et al. Catalysing the development and introduction of paediatric drug formulations for children living with HIV: a new global collaborative framework for action. J Lancet. 2018;5:e259–e264.
    1. Malati CY, Golin R, O’Brien L, et al. Pursuing use of optimal formulations for paediatric HIV epidemic control – a look at the use of LPV/r oral pellets and oral granules. J Int AIDS Soc. 2019;22:e25267.
    1. Waalewijn H, Chan MK, Bollen PDJ, et al.; ODYSSEY Trial Team. Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial. Lancet HIV. 2022;9:E341–E352.
    1. Bollen PDJ, Moore CL, Mujuru HA, et al.; ODYSSEY trial team. Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial. Lancet HIV. 2020;7:E533–E544.

Substances

LinkOut - more resources